Does ALIROCUMAB Cause Injection site dryness? 14 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 14 reports of Injection site dryness have been filed in association with ALIROCUMAB (Praluent). This represents 0.1% of all adverse event reports for ALIROCUMAB.
14
Reports of Injection site dryness with ALIROCUMAB
0.1%
of all ALIROCUMAB reports
0
Deaths
1
Hospitalizations
How Dangerous Is Injection site dryness From ALIROCUMAB?
Of the 14 reports, 1 (7.1%) required hospitalization.
Is Injection site dryness Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ALIROCUMAB. However, 14 reports have been filed with the FAERS database.
What Other Side Effects Does ALIROCUMAB Cause?
Myalgia (1,571)
Product dose omission (1,354)
Injection site pain (1,220)
Muscle spasms (1,113)
Arthralgia (993)
Fatigue (922)
Pain (892)
Pain in extremity (888)
Product dose omission issue (864)
Injection site bruising (821)
What Other Drugs Cause Injection site dryness?
DUPILUMAB (320)
ETANERCEPT (37)
ADALIMUMAB (31)
SARILUMAB (29)
BELIMUMAB (21)
PEGINTERFERON BETA-1A (21)
TREPROSTINIL (16)
GLATIRAMER (13)
INTERFERON BETA-1A (13)
TIRZEPATIDE (12)
Which ALIROCUMAB Alternatives Have Lower Injection site dryness Risk?
ALIROCUMAB vs ALISKIREN
ALIROCUMAB vs ALISKIREN HEMIFUMARATE
ALIROCUMAB vs ALISKIREN\HYDROCHLOROTHIAZIDE
ALIROCUMAB vs ALIZAPRIDE
ALIROCUMAB vs ALLANTOIN